EGFR and glioma: Most prominently deployed against CD19-expressing cells in haematological malignancies, where they have achieved remarkable clinical efficacy [149], the only current clinically relevant mutant antigen target for CAR-T cells is the exon 2-7 deletion vIII variant of EGFR, commonly expressed in glioma [150,151].